Avi Bzura - Kadimastem External Director
| KDST Stock | ILA 461.60 1.00 0.22% |
Director
Mr. Avi Bzura serves as External Director at Kadimastem Ltd since September 1, 2013. He is Chairman of the Financial Statements Auditing committee and Member of the Audit and Compensation committees. His work experience includes the following roles Directorship at PLT Financial Services Ltd, Chief Executive Officer at Bank of Jerusalem Ltd. for three and a half years, Chairman of the Board at Jerusalem Portfolio Management for three and a half years and Corporationrationrate Executive at Mortgage Bank and Poalim Bank for two and a half years. He holds a Bachelors degree in Economics from Tel Aviv University and a MBA degree from Bar Ilan University. since 2013.
| Age | 53 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 972 73 797 1600 |
| Web | https://www.kadimastem.com |
Kadimastem Management Efficiency
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Raphael Hofstein | BioLine RX | 67 | |
| Sanford Zweifach | Compugen | 60 | |
| Michael Anghel | BioLine RX | 78 | |
| Mali Zeevi | BioLine RX | 40 | |
| Dov Hershberg | Compugen | 74 | |
| Arie Ovadia | Compugen | 67 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Kinneret Savitsky | Compugen | 50 | |
| Eran Perry | Compugen | N/A | |
| Batia Avital | Bonus Biogroup | 54 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Jacob Friedman | BioLine RX | 43 | |
| Joshua Shemer | Compugen | 63 | |
| Gilead Halevy | Compugen | 51 | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
| Gil Shapira | Bonus Biogroup | 56 | |
| Avraham Molcho | BioLine RX | 59 | |
| Avi Slonim | Bonus Biogroup | 38 | |
| Nurit Benjamini | BioLine RX | 51 | |
| Michal Preminger | Compugen | N/A | |
| BarbaraJean Bormann | BioLine RX | 55 | |
Management Performance
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 |
Kadimastem Leadership Team
Elected by the shareholders, the Kadimastem's board of directors comprises two types of representatives: Kadimastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kadimastem. The board's role is to monitor Kadimastem's management team and ensure that shareholders' interests are well served. Kadimastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kadimastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keren Tzlill, External Director | ||
| Yossi Nizhar, Vice President - Finance | ||
| Ilan Hadar, External Director | ||
| Arik Hasson, Exec Devel | ||
| Yossi BenYossef, Honorary Consultant | ||
| Michal Izrael, VP Diseases | ||
| David Sultan, Independent Director | ||
| Asaf Shiloni, Chief Officer | ||
| Michel Revel, Chief Scientific Officer-Services Provider, Director | ||
| Ram Epstein, Chief Executive Officer, Director | ||
| Joseph Eldor, Director | ||
| Michal Harel, Vice President - Research & Development-ALS & Neurodegenerative Diseases | ||
| Pr MD, Chief CoFounder | ||
| Avi Bzura, External Director | ||
| Abraham Meizler, Director | ||
| Adina Makover, External Director | ||
| Yigal Fatran, Director | ||
| Eli Opper, Chairman of the Board | ||
| Ziv Ironi, External Director | ||
| Neta Lavon, Vice President - Operations | ||
| Julien Ruggieri, Director | ||
| Arye Hasson, Executive Vice President-Research & Development | ||
| Yehuda Feinberg, Vice President - Finance |
Kadimastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kadimastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Shares Owned By Insiders | 53.72 % | |||
| Shares Owned By Institutions | 8.31 % | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Net Income | (26.27 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kadimastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |